View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 10, 2011

Opexa Tovaxin drug receives FDA fast-track designation

The US Food and Drug Administration (FDA) has granted fast-track designation to Opexa Therapeutics' Tovaxin drug candidate, used to treat secondary progressive multiple sclerosis.

The US Food and Drug Administration (FDA) has granted fast-track designation to Opexa Therapeutics’ Tovaxin drug candidate, used to treat secondary progressive multiple sclerosis.

The fast-track status will facilitate to develop and expedite the review of drugs intended to treat serious or life-threatening conditions.

Fast-track priority review products are expected to be approved during the first review cycle, resulting in a halved review period compared to those without the designation.

Opexa president and CEO Neil Warma said the receipt of fast-track designation will advance Tovaxin through the clinical and regulatory process.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology